Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study)

British Journal of Ophthalmology

Volumn 93, Issue 5, 2009, Pages 688-691

  Da Lucena, D R ^a   Ribeiro, J A S ^a   Costa, R A ^a,b   Barbosa, J C ^c   Scott, I U ^d   De Figueiredo Pontes, L L ^a   Jorge, R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Hospital de Olhos de Araraquara   (Brazil)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; ENDOPHTHALMITIS; ERYTHROCYTE COUNT; FEMALE; HUMAN; INTRAOCULAR HEMORRHAGE; MALE; OUTCOME ASSESSMENT; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VITRECTOMY; BLEEDING; INJECTION; MIDDLE AGED; PREMEDICATION; PROSPECTIVE STUDY; VITREOUS BODY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BLOOD LOSS, SURGICAL; DIABETIC RETINOPATHY; ERYTHROCYTE COUNT; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PREANESTHETIC MEDICATION; PROSPECTIVE STUDIES; RETINAL DETACHMENT; TREATMENT OUTCOME; VITRECTOMY; VITREOUS BODY;

EID: 66149143624     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.151233     Document Type: Article

References (20)

1. Rice TA, Michels RG, Rice EF. Vitrectomy for diabetic traction retinal detachment involving the macula. Am J Ophthalmol 1983;95:22-33.
2. Fong DS, Ferris FL 3rd, Davis MD, et al. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol 1999;127:137-141.
3. Ho T, Smiddy WE, Flynn HW Jr. Vitrectomy in the management of diabetic eye disease. Surv Ophthalmol 1992;37:190-202.
4. Aaberg TM, Abrams GW. Changing indications and techniques for vitrectomy in management of complications of diabetic retinopathy. Ophthalmology 1987;94:775- 779.
5. Meier P, Wiedemann P. Vitrectomy for traction macular detachment in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 1997;235:569-574.
6. Miller SA, Butler JB, Myers FL, et al. Pars plana vitrectomy. Treatment for tractional macula detachment secondary to proliferative diabetic retinopathy. Arch Ophthalmol 1980;98:659- 664.
7. Ishikawa K, Honda S, Tsukahara Y, et al. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye. Published Online First: 21 September 2007. doi:10.1038/sj.eye.6702983.
8. de Bustros S, Glaser BM, Johnson MA. Thrombin infusion for the control of intraocular bleeding during vitreous surgery. Arch Ophthalmol 1985;103:837-839.
9. Thompson JT, Glaser BM, Michels RG, et al. The use of intravitreal thrombin to control hemorrhage during vitrectomy. Ophthalmology 1986;93:279-282.
10. Thompson JT, de Bustros S, Michels RG, et al. Results and prognostic factors in vitrectomy for diabetic traction retinal detachment of the macula. Arch Ophthalmol 1987;105:497-502.
11. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin®) for choroidal neovascularization in AMD (IBeNA Study): Phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006;47:4569-4578.
12. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007;27:141-149.
13. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin)in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 2007;245:1273- 1280.
14. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339.
15. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) forneovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
16. Tonello M, Costa RA, Almeida FP, et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008;86:385-389.
17. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-15.
18. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006;26:699-700.
19. Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006;26:1006-1013.
20. Henry JB. Clinical diagnosis and management by laboratory methods. 19th edn. Philadelphia: WB Saunders, 1996:1551-1556.